Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This prospective, multicenter clinical study evaluates the efficacy and safety of NALIRIFOX in combination with Stereotactic Body Radiation Therapy (SBRT) for patients with locally advanced unresectable pancreatic cancer. The primary endpoint is progression-free survival (PFS), with secondary endpoints including objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety assessment. The study involves two cohorts: Cohort 1 (early SBRT after 1 cycle of NALIRIFOX) and Cohort 2 (late SBRT after 6-8 cycles of NALIRIFOX). A total of 42 participants are expected to be enrolled, with a follow-up period of at least 24 months. This trial aims to provide a novel therapeutic option for this patient population.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony nowotwór trzustki, który nie da się operacyjnie usunąć
- •Brak wcześniejszej chemioterapii lub radioterapii raka trzustki
- •Dobre funkcjonowanie ogólne (ECOG 0-1)
- •Prawidłowe wyniki badań krwi i funkcji nerek
- •Możliwość podpisania świadomej zgody
✗ Disqualifies
- •Historia innych nowotworów (poza rakiem skóry)
- •Aktywne infekcje lub poważne problemy zdrowotne
- •Ciąża lub karmienie piersią
- •Alergia na składniki leku
- •Niekontrolowana cukrzyca, niewydolność serca lub choroby nerek
- •Uczestnictwo w innych badaniach w ostatnie 30 dni
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Shandong Cancer Hospital and Institute
Jinan, China
Trial contact
Jinbo Yue, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.